AVALON GLOBOC.NEW -,0001
AVALON GLOBOC.NEW -,0001
Acción · US05344R2031 · ALBT · A3D4QG (XNCM)
Resumen Indicadores financieros
2,99 EUR
-4,48 % -0,14 EUR
Frankfurt (XNAS) · Precios actuales y gráficos en MoneyPeak
06.06.2025 17:46

Cotizaciones actuales de AVALON GLOBOC.NEW -,0001

BolsaTickerMonedaÚltima operaciónPrecioVariación diaria
XNAS: NASDAQ
NASDAQ
ALBT
USD
06.06.2025 17:46
3,41 USD
3,42 USD
-0,15 %

Rendimiento

Día Semana Mes 3 meses 6 meses 1 año 5 años
-0,45 % -0,15 % -9,75 % -52,47 % -22,41 % -54,13 % -98,73 %

Perfil de la empresa para AVALON GLOBOC.NEW -,0001 Acción

Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.

Datos de la empresa

Nombre AVALON GLOBOC.NEW -,0001
Empresa Avalon GloboCare Corp.
Símbolo ALBT
Sitio web https://www.avalon-globocare.com
Mercado principal XNCM Frankfurt
WKN A3D4QG
ISIN US05344R2031
Tipo de valor Acción
Sector Real Estate
Industria Real Estate - Services
CEO Dr. David K. Jin M.D., Ph.D.
País Estados Unidos de América
Moneda EUR
Empleados 0,0 T
Dirección 4400 Route 9 South, 07728 Freehold
Fecha de OPV 2018-03-27

Splits de acciones

Fecha Split
28.10.2024 1:15

Cambios de identificador

Fecha De A
10.11.2022 AVCO ALBT

Símbolos de cotización

Nombre Símbolo
NASDAQ ALBT

Otras acciones

Los inversores que tienen AVALON GLOBOC.NEW -,0001 también tienen las siguientes acciones en su cartera:
META PLATF. 23/33
META PLATF. 23/33 Bono
NN GRP 23/43 FLR MTN
NN GRP 23/43 FLR MTN Bono
La plataforma financiera MoneyPeak rastrea y analiza inversiones y carteras. Desde depósitos de valores hasta compras de criptomonedas.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.
Aviso legal Protección de datos Blog Comunidad Comentarios Changelog
Im App Store herunterladen Bei Google Play herunterladen
Todos los derechos reservados © LCP GmbH 2025